pustulosis palmoplantaris ppp - HEALTHY
Seeking Alpha: MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day Business Wire: LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP) LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP) The American Journal of Managed Care: Biologics Linked With Development of Palmoplantar Pustulosis, Palmoplantar Pustular Psoriasis Adalimumab and infliximab were the most common biologic therapies associated with the onset of palmoplantar pustulosis and palmoplantar pustular psoriasis. Use of biologic therapies such as adalimumab ... The Dermatology Division of the U.S.
Context Explanation
Food and Drug Administration has granted Fast Track designation to sonelokimab in moderate-to-severe palmoplantar pustulosis supported by positive results from the ... The phase 2a proof-of-concept trial will recruit up to 135 adult patients with mild to severe PPP to investigate the efficacy and safety of delgocitinib cream compared to cream vehicle. Delgocitinib ...